Share This Page
Litigation Details for Biogen MA Inc. v. Somerset Therapeutics, LLC (D. Del. 2026)
✉ Email this page to a colleague
Biogen MA Inc. v. Somerset Therapeutics, LLC (D. Del. 2026)
| Docket | ⤷ Start Trial | Date Filed | 2026-06-22 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Parties | SOMERSET THERAPEUTICS, LLC | ||
| Patents | 8,361,977; 8,980,853; 9,717,750 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Biogen MA Inc. v. Somerset Therapeutics, LLC
Details for Biogen MA Inc. v. Somerset Therapeutics, LLC (D. Del. 2026)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2026-06-22 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation Summary and Patent Analysis: Biogen MA Inc. v. Somerset Therapeutics, LLC (1:26-cv-00735)
Executive summary: The docket entry for Biogen MA Inc. v. Somerset Therapeutics, LLC, 1:26-cv-00735 indicates an active federal case filed in 2026, but the provided information does not include the complaint, asserted patents, FDA product details, Orange Book listings, or any claim/construction or settlement records. Without those case-specific filings and identified patents, a complete, accurate litigation summary and IP strength analysis cannot be produced.
What is Biogen MA Inc. v. Somerset Therapeutics, LLC (1:26-cv-00735) about?
Direct answer: The available case identifier confirms the matter exists, but no substantive allegations, target drug, or asserted patent set is provided, so the litigation cannot be characterized by claims, infringement theory, or patent scope.
What do plaintiffs typically plead in Biogen patent cases under Hatch-Waxman?
Without the actual complaint, the only reliable statement is structural: these cases typically involve one or more of the following, depending on the underlying FDA submission:
- Infringement of one or more listed patents in the FDA Orange Book (or unlisted patents in rare contexts).
- Paragraph IV and related remedies against generic entry if the defendant files a qualifying application (often ANDA) with a “not infringed / not valid” position.
- Declaratory judgment of noninfringement and invalidity in counter-suits (depending on the procedural posture).
No information is provided here to tie any of those items to 1:26-cv-00735.
Which patents are asserted in Biogen MA Inc. v. Somerset Therapeutics, LLC?
Direct answer: Not provided. The docket identifier alone is insufficient to name asserted patents, their publication/application numbers, priority dates, or remaining term.
How to determine the asserted patent list from the docket (what matters for analysis)?
An IP-focused litigation analysis must map:
- Asserted patent numbers (and any family members)
- Expiration dates and pediatric exclusivity impacts
- Whether patents are composition, formulation, method of use, or manufacturing
- Whether asserted claims correspond to an Orange Book listed drug or a broader technical field
Those inputs are not available in the provided prompt.
Is this case likely an ANDA (generic) or a biosimilar dispute?
Direct answer: Unknown from the provided information.
What procedural fingerprints would clarify the pathway?
A correct analysis would identify:
- Whether the defendant’s submission is an ANDA (small molecule) with Paragraph IV notices
- Or a BLA biosimilar pathway with biosimilar-specific litigation patterns
But no FDA pathway, product name, or submission type is given.
What is the litigation posture in 1:26-cv-00735?
Direct answer: Unknown. No status information (e.g., complaint filed, motion to dismiss, preliminary injunction briefing, Markman schedule, claim construction order, summary judgment, trial schedule, settlement) is provided.
Which milestones drive value in patent litigation?
A business-relevant analysis depends on timing and procedural posture:
- Early stage: TRO/preliminary injunction risk windows
- Mid stage: claim construction outcomes that narrow infringement/validity
- Late stage: damages, injunction scope, and settlement terms (if reached)
No such milestones are supplied.
Has there been any settlement in Biogen MA Inc. v. Somerset Therapeutics?
Direct answer: Not provided.
Why settlement terms determine generic entry economics
If settlement exists, analysis must cover:
- “Launch date” carveouts
- Design-around obligations (formulation and process constraints)
- Royalty or milestone terms
- Stipulated dismissal with prejudice or without prejudice
- Scope limits by patent and claim type
No settlement information is present.
What is the Orange Book status of the relevant Biogen product in this case?
Direct answer: Not provided.
What an Orange Book-based analysis requires
A full Orange Book section must identify:
- The NDA and listed patents
- Expiration dates, exclusivity periods, and remaining FDA exclusivity
- Which patents are listed for the drug and how the defendant’s carveouts map
The prompt provides no drug identity, NDA, or Orange Book record.
How strong is the patent estate asserted by Biogen in this dispute?
Direct answer: Cannot be calculated from the provided information.
What “strength” analysis depends on
A litigation-grade strength view typically quantifies:
- Claim breadth and dependency structure
- Prior art landscape (obviousness risk)
- Enablement and written description issues
- Infringement alignment with the defendant’s ANDA/biosimilar technical submission
- Federal Circuit or district-level precedent affecting those claim types
None of the asserted-patent specifics are available.
What generic entry risks exist for Somerset Therapeutics if Biogen prevails?
Direct answer: Cannot be assessed without knowing:
- The FDA product and submission type
- The patents asserted and likely injunction scope
- Whether there is a court-enforced launch trigger tied to a specific patent expiry or settlement term
When does patent or exclusivity expire for the relevant product, and when could generics launch?
Direct answer: Not provided.
The required timeline elements
A correct exclusivity-and-expiration timeline needs:
- Patent expiration dates for each asserted Orange Book patent
- Any pediatric exclusivity extensions
- Any non-patent exclusivities (e.g., 5-year/7-year depending on product category)
- FDA regulatory milestones that determine the actual launch window
No dates are included.
Are there related litigations involving Biogen and Somerset (or overlapping counsel/parties)?
Direct answer: Not provided.
What cross-case mapping would normally show
A robust analysis identifies:
- Same asserted patents used in multiple defendant cases
- Parallel PTAB challenges (post-grant review) that affect validity
- Coordinated settlements or consistent claim construction outcomes
No related litigation data is provided.
Key Takeaways
- The case identifier confirms Biogen MA Inc. v. Somerset Therapeutics, LLC, 1:26-cv-00735 is active in federal court in 2026.
- A defensible litigation summary and IP analysis requires the complaint, asserted patents, accused product details, FDA submissions, Orange Book identifiers, and procedural posture, none of which are included in the provided information.
- Without those case-specific records, any statement about asserted patents, validity/infringement theories, timeline, injunction risk, or settlement would be incomplete.
FAQs
- What district court is handling Biogen MA Inc. v. Somerset Therapeutics, LLC (1:26-cv-00735)?
- Does 1:26-cv-00735 involve an ANDA Paragraph IV notice or another FDA pathway?
- Which specific Biogen patents are asserted, and what claims are in dispute?
- What procedural stage is the case in as of the latest docket activity?
- Is Somerset’s product tied to a specific NDA/Orange Book listing, and which patents are listed for that drug?
References
- Federal case docket: Biogen MA Inc. v. Somerset Therapeutics, LLC, No. 1:26-cv-00735.
More… ↓
